

Application No.:  
Page 4

24. The pharmaceutical composition of claim 23, wherein the monoclonal antibody is a single chain antibody.


25. The pharmaceutical composition of claim 16, wherein the antibody is directed against a surface marker present on B cell lymphomas.

A2  
26. (amended) The pharmaceutical composition of claim 25, wherein the antibody is selected from the group consisting of RFB4 and LL2.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200

Respectfully submitted,

  
Jean M. Lockyer, Ph.D.  
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
JML  
SF 1252302 v1

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

1. (amended) A selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity [joined] covalently linked to an antibody directed against a surface marker specific to a B cell, wherein the cytotoxic reagent is at least 100 times more cytotoxic to target cells bearing a B cell marker than a comparison reagent comprised of the same antibody joined to the human non-toxic RNase eosinophil-derived neurotoxin (EDN).

26. The pharmaceutical composition of claim 25, wherein the antibody is selected from the group consisting of RFB4[, LL1] and LL2

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100